全文获取类型
收费全文 | 2114篇 |
免费 | 138篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 31篇 |
妇产科学 | 30篇 |
基础医学 | 319篇 |
口腔科学 | 72篇 |
临床医学 | 202篇 |
内科学 | 613篇 |
皮肤病学 | 72篇 |
神经病学 | 111篇 |
特种医学 | 60篇 |
外科学 | 234篇 |
综合类 | 2篇 |
一般理论 | 2篇 |
预防医学 | 129篇 |
眼科学 | 36篇 |
药学 | 180篇 |
中国医学 | 5篇 |
肿瘤学 | 146篇 |
出版年
2023年 | 24篇 |
2022年 | 34篇 |
2021年 | 79篇 |
2020年 | 38篇 |
2019年 | 52篇 |
2018年 | 69篇 |
2017年 | 41篇 |
2016年 | 50篇 |
2015年 | 57篇 |
2014年 | 74篇 |
2013年 | 92篇 |
2012年 | 171篇 |
2011年 | 170篇 |
2010年 | 107篇 |
2009年 | 87篇 |
2008年 | 132篇 |
2007年 | 155篇 |
2006年 | 112篇 |
2005年 | 125篇 |
2004年 | 111篇 |
2003年 | 84篇 |
2002年 | 92篇 |
2001年 | 13篇 |
2000年 | 33篇 |
1999年 | 37篇 |
1998年 | 10篇 |
1997年 | 11篇 |
1996年 | 12篇 |
1995年 | 17篇 |
1994年 | 13篇 |
1993年 | 5篇 |
1992年 | 22篇 |
1991年 | 20篇 |
1990年 | 12篇 |
1989年 | 16篇 |
1988年 | 10篇 |
1987年 | 8篇 |
1986年 | 10篇 |
1985年 | 12篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1980年 | 4篇 |
1979年 | 7篇 |
1978年 | 2篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1974年 | 3篇 |
1972年 | 4篇 |
1971年 | 2篇 |
1967年 | 4篇 |
排序方式: 共有2262条查询结果,搜索用时 31 毫秒
21.
Atsushi Masuyama Hitomi Kobayashi Yasuyuki Kobayashi Isamu Yokoe Yusuke Sugimura Keiichiro Maniwa Hiroshi Sato Tsuyoshi Ishida Yuki Hatanaka 《Modern rheumatology / the Japan Rheumatism Association》2013,23(2):379-385
We present a patient who had adult-onset Still’s disease (AOSD) complicated by thrombotic thrombocytopenic purpura (TTP) that resulted in retinal microangiopathy and rapidly fatal cerebral edema. The patient was a 37-year-old male who developed fever, eruption, arthritis and hepatic dysfunction, that, based on close examination, was diagnosed as AOSD. Despite treatment with corticosteroids, the patient developed acute visual field defect, neurological deterioration including convulsions and impaired consciousness, as well as acute renal failure that ultimately resulted in death. Pathological examination of autopsy specimens revealed multiple fibrin thrombi disseminated in small vessels of the brain and kidney, which was consistent with TTP, along with marked cerebral edema. Although TTP has rarely been reported in association with AOSD, awareness of the possible coexistence of these two diseases is important for diagnosis and treatment. 相似文献
22.
23.
Mariko Endou Hitomi Aoki Tatsushi Kobayashi Takahiro Kunisada 《The Journal of dermatology》2014,41(8):716-723
Epidermal melanocyte precursors migrate into developing hair follicles to form the melanocyte stem cell system required to supply pigmented melanocytes necessary for hair pigmentation in repetitive hair cycles. Hair graying is caused by irreversible defects in the self‐renewal and/or development of follicular melanocyte stem cells in the hair follicles. To investigate the mechanism(s) of hair graying during the normal aging process, we established a hair graying model in mice by repeatedly plucking or shaving trunk hairs. We repeatedly plucked or shaved trunk hairs to induce and accelerate the hair graying and counted the gray hairs. By using this functional model of hair graying in mice, we assessed the effects of genes known to affect melanocyte development, such as Kitl, hepatocyte growth factor (HGF) and endotheline 3 (ET3). After increasing the total numbers of cumulative hair cycles by plucking or shaving, we observed a significant increase in the gray hair of C57BL/6 mice. Kitl expression in the skin was the most effective for preventing hair graying and a significant effect was also confirmed for HGF and ET3 expression. The repeated hair plucking or shaving led to hair graying without any genetic lesion. Kitl is a more effective factor for prevention of hair graying than HGF or ET3. Our simple model of hair graying may provide a basic tool for screening the molecules or reagents preventing the progression of hair graying. 相似文献
24.
25.
Eiko Hasegawa Masahiro Kobayashi Yusuke Kawamura Hiromi Yatsuji Hitomi Sezaki Tetsuya Hosaka Norio Akuta Fumitaka Suzuki Yoshiyuki Suzuki Yasuji Arase Kenji Ikeda Hiromitsu Kumada 《Hepatology research》2007,37(10):793-800
Background: We assessed the efficacy and anticarcinogenic effects of interferon (IFN) therapy in patients with hepatitis C virus (HCV)-related cirrhosis. Methods: The study subjects were 123 Japanese patients with HCV-related cirrhosis with genotype 1b low viral load or genotype 2 who received IFN from 1989 to 2005 (18 patients continue to receive IFN therapy). They included 81 men and 42 women aged 29-74 years (median, 56 years). Results: Univariate analysis identified four parameters that significantly influenced SVR; viral load (low HCV concentration, P < 0.001), duration of IFN therapy (>/= 52 weeks, P = 0.029), daily dose of IFN (>/= 6 million units, P = 0.018), induction therapy (presence, P = 0.010) and choline esterase (> 1.0 DeltapH, P = 0.037). Multivariate analysis identified viral load (risk ratio = 6.329, P < 0.001) and daily dose of IFN (risk ratio = 2.62, P = 0.042) as two independent parameters thatinfluenced SVR. During the observation period, newly developed hepatocellular carcinoma (HCC) was detected in 22 patients. The rates of development of HCC in patients with SVR were 5.8% at the fifth year and 10.3% at the 10th year, compared with 25.8% at the fifth year and 42.5% at the 10th year in non-SVR patients. Multivariate analysis showed that IFN efficacy (SVR) was the only independent factor of hepatocarcinogenesis (hazard ratio: 0.185, 95% confidence interval: 0.042-0.810, P = 0.025) Conclusion: Among patients with HCV-related cirrhosis, the rate of development of HCC is significantly less in patients with SVR. 相似文献
26.
We report two cases of septic pulmonary embolism associated with periodontitis. Chest CT revealed multiple nodular shadows with features characteristic of septic pulmonary embolism in both patients. Both patients had toothache, fever, and chest pain, and showed findings of periodontitis at initial presentation. Antimicrobial agents combined with dental surgery were successful in treatment. While septic pulmonary embolism from the lesions of periodontitis appears to be rare, periodontitis remains important in the differential diagnosis of septic pulmonary embolism. 相似文献
27.
Kayoko Kasuya Yusuke Kawamura Masahiro Kobayashi Junichi Shindoh Yuta Kobayashi Akira Kajiwara Soichi Iritani Shunichiro Fujiyama Tetsuya Hosaka Satoshi Saitoh Hitomi Sezaki Norio Akuta Fumitaka Suzuki Yoshiyuki Suzuki Kenji Ikeda Yasuji Arase Yuichiro Eguchi Masaji Hashimoto Hiromitsu Kumada 《Internal medicine (Tokyo, Japan)》2021,60(3):345
Objective A survival benefit was demonstrated for ramucirumab (RAM) in patients with unresectable hepatocellular carcinoma (uHCC) and α-fetoprotein (AFP) concentrations ≥400 ng/mL who had previously received sorafenib (SOR). However, it is unclear whether RAM has a similar efficacy in patients with uHCC that progresses after lenvatinib (LEN) treatment. This study aimed to evaluate the early anti-tumor response to RAM as a second-line treatment for advanced uHCC after LEN treatment. Methods We retrospectively assessed the efficacy and safety of RAM at 6 weeks after initiation. The therapeutic effects were evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1. Patients We evaluated 7 patients with uHCC who received RAM as a second- or third-line treatment after LEN failure. Results The disease control rate (DCR) was 28.6% (2 of 7 patients). After the initiation of RAM, a rapid disease progression resulted in 1 patient death after 19 days. The median progression-free survival (PFS) was 41 days. There were no grade 3 or 4 treatment-related adverse events. At 6 weeks, there was no deterioration in the modified albumin-bilirubin (mALBI) grade. In patients with an imaging response of stable disease (SD), the rate of AFP production decreased from the baseline. Conclusion RAM may have a therapeutic potential for the suppression of uHCC progression in patients previously treated with LEN, as well as for maintaining the liver function during treatment. Evaluating the AFP trends may therefore be useful for predicting RAM effectiveness. 相似文献
28.
Toshio Kinoshita Hitomi Yuzawa Kazuhiko Natori Ryo Wada Shintaro Yao Kensuke Yano Katsuya Akitsu Hideki Koike Masaya Shinohara Tadashi Fujino Hideaki Shimada Takanori Ikeda 《Journal of cardiology》2021,77(4):388-394
BackgroundDealing with chemotherapy-related cardiac dysfunction (CTRCD) remains a significant problem complicated by the difficulty in early detection of cardiotoxicity. Electrocardiogram (ECG) is expected to be the most realistic methodology due to lower cost-performance and non-invasiveness. We investigated the long-term visual fluctuations in the ECG waveforms in patients with chronic doxorubicin (DOX)-induced cardiotoxicity to identify ECG indices for the early detection of cardiotoxicity.MethodsWe conducted a retrospective case series study by reviewing the medical records of 470 consecutive patients with malignant lymphoma who were treated with DOX at our institute between January 2010 and December 2017. Of them, 23 (4.9%) patients developed left ventricular dysfunction and were diagnosed with CTRCD using echocardiography. We assessed the ECG indices on 12-lead ECG recordings before and after treatment in 15 patients; eight patients were excluded due to conduction disturbances or atrial fibrillation.ResultsCTRCD was detected at a median of 475 (interquartile range, IQR: 341–1333) days after initiating chemotherapy. The evaluation of ECG indices preceding CTRCD development was performed 93 (IQR: 52–232) days before the detection of CTRCD. In the stage of CTRCD, the most significant ECG change was T-wave flattening in leads V3–V6 (12 patients, 80%). Additionally, QTa prolongation was observed in leads I and aVL (n = 10, 66%), leads II, III, and aVF (n = 9, 60%), and leads V3–V6 (n = 10, 73%). These ECG changes were not observed before the treatment but were detected mildly in the pre-CTRCD stage, which subsequently worsened in the CTRCD stage.ConclusionsThis study indicated that T-wave changes and QTa prolongation may be useful as an early indicator before the onset of CTRCD in patients with DOX-induced cardiotoxicity. 相似文献
29.
30.
Norio Akuta Fumitaka Suzuki Taito Fukushima Yusuke Kawamura Hitomi Sezaki Yoshiyuki Suzuki Tetsuya Hosaka Masahiro Kobayashi Tasuku Hara Mariko Kobayashi Satoshi Saitoh Yasuji Arase Kenji Ikeda Hiromitsu Kumada 《Journal of clinical microbiology》2013,51(9):2862-2868
It is often difficult to predict the response to telaprevir-pegylated interferon (PEG-IFN)-ribavirin triple therapy and the appearance of telaprevir-resistant variants. The present study determined the predictive factors of a sustained virological response (SVR) to 12- or 24-week triple therapy (T12PR12 or T12PR24, respectively) in 194 Japanese patients infected with hepatitis C virus genotype 1b (HCV-1b). The study also evaluated whether ultradeep sequencing technology can predict at baseline the emergence of resistant variants after the start of therapy. Analysis of the data of the entire group indicated that an SVR was achieved in 78% of the patients. Multivariate analysis identified IL28B rs8099917 (genotype TT), the substitution of amino acid (aa) 70 (Arg70), response to prior treatment (naive or relapse), PEG-IFN dose (≥1.3 μg/kg of body weight), and treatment regimen (T12PR24) as significant determinants of SVR. Among patients of the T12PR24 group, 92% with genotype TT achieved an SVR, irrespective of a substitution at aa 70. In patients with the non-TT genotype, an SVR was achieved in 76% of those with Arg70, while only 14% of patients with the non-TT genotype, Gln70(His70), and nonresponse to ribavirin combination therapy achieved an SVR. Ultradeep sequencing was conducted for 17 patients who did not achieve an SVR to determine the emergence of resistant variants during therapy. De novo resistant variants were detected in 16 of 17 patients (94%), regardless of the variant frequencies detected at baseline. In conclusion, the results indicate that the response to triple therapy can be predicted by the combination of host, viral, and treatment factors and that it is difficult to predict at baseline the telaprevir-resistant variants that emerge during triple therapy, even with the use of ultradeep sequencing. 相似文献